AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04593238
Drug: Calcium Hydroxide Paste - Non-Setting
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
Trial: NCT03875313
Drug: CB-839
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
Trial: NCT01939691
Drug: Nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nepafenac 0.1% - NSAID eyedrop
Trial: NCT01939691
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisolone acetate 1% - corticosteroid eyedrop
Trial: NCT00366249
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
Trial: NCT05768282
Drug: Oral prednisolone (30mg/day) for 28 days
RxNorm normalized name: Prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone was started at a dose of 30 mg/day on the third day after RFA, and continued for 4 weeks.
Trial: NCT00754065
Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
Trial: NCT03106922
Drug: PMF104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for oral solution:~* Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~* Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water
Trial: NCT03658616
Drug: WO3970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of cream to each axilla
Trial: NCT03658616
Drug: Placebo (WO3988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of cream to each axilla
Trial: NCT02639637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
Trial: NCT01053325
Drug: SP IPT
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulphadoxine-pyrimethamine
Trial: NCT01505166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
Trial: NCT04115423
Drug: Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
Trial: NCT02446340
Drug: dalazatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
Trial: NCT02446340
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
Trial: NCT00683800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
Trial: NCT01074294
Drug: OPDC-34712
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPDC-34712 tablets, daily, Orally.
Trial: NCT01074294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching-placebo tablets, daily, Orally.
Trial: NCT01074294
Drug: Stimulant Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
Trial: NCT02247375
Drug: High dose of BIIL 284 BS tablets
RxNorm normalized name: betamethasone 0.284 MG/ML / gentamicin 0.57 MG/ML [Betagen brand of Betamethasone and Gentamicin]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02247375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04278755
Drug: Drospirenone-Ethinyl Estradiol Oral Tablet
RxNorm normalized name: drospirenone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
Trial: NCT01798667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of DA-8031, undistinguishable
Trial: NCT00112359
Drug: AZLI 75 mg three times a day (TID)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00455650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
Trial: NCT02575924
Drug: sequential medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
Trial: NCT03618758
Drug: mFOLFOX6 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)
Trial: NCT00312208
Drug: docetaxel, doxorubicin, cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
Trial: NCT00312208
Drug: Docetaxel,doxorubicin, cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
Trial: NCT03471585
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
Trial: NCT00588471
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
Trial: NCT00588471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
Trial: NCT02492412
Drug: HE 10
RxNorm normalized name: Mycelex Troche 10mg Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002945
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT02620306
Drug: Fimsartan 60mg~120mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
Trial: NCT02620306
Drug: Fimsartan 60mg~120mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
Trial: NCT03005119
Drug: PTL201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
Trial: NCT03005119
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo seamless gelatin matrix green beads containing excipients only
Trial: NCT03190603
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
Trial: NCT01913314
Drug: [^14C]-LY2835219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as oral solution
Trial: NCT03836222
Drug: PCS499
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR tablet
Trial: NCT01400958
Drug: Nuvigil®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuvigil® 150 mg/day x 42 days THEN, No More Drug
Trial: NCT01400958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo x 42 days; THEN, No More Placebo
Trial: NCT00558454
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous succinate mixture
Trial: NCT03492866
Drug: Gentamicin Sulfate
RxNorm normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical treatment of 1 side of the scalp twice daily during 6 months
Trial: NCT01079949
Drug: r-hLH + r-hFSH
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
Trial: NCT01079949
Drug: Recombinant Human Choriogonadotropin (r-hCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
Trial: NCT01204333
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
Trial: NCT03102177
Drug: Administration of stable Isotope labeled levothyroxine
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of single dose of stable isotope carbon-13 labeled levothyroxine and measurement of blood levels of stable isotope-labeled levothyroxine
Trial: NCT01921946
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00355849
Drug: Human Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient specific dose, inhaled, before meals, 52 weeks
Trial: NCT00514202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT02286557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00160394
Drug: Duac® Gel / Differin® Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00091936
Drug: Standard TB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00067470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00067470
Drug: N-acetylgalactosamine 4-sulfatase
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02120157
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy administration
Trial: NCT02195817
Drug: Selincro® 18 mg with continuous psychosocial support: Cohort A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00441103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered subcutaneously three times a week for 16 weeks.
Trial: NCT00873808
Drug: demeclocycline hydrochloride
RxNorm normalized name: Demeclocycline Hydrochloride
DrugBank: Demeclocycline (DB00618)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00873808
Drug: ibandronate sodium
RxNorm normalized name: Ibandronate Sodium
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00873808
Drug: tetracycline hydrochloride
RxNorm normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00873808
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04345406
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alexoquine
Trial: NCT01768468
Drug: JOINS tablet
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet at each time, 3 times a day
Trial: NCT00194272
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two dose methotrexate
Trial: NCT00016198
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00016198
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00016198
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04621669
Drug: SHR3680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg
Trial: NCT04621669
Drug: Rosuvastatin calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg
Trial: NCT01848899
Drug: Ioxaglate
RxNorm normalized name: ioxaglate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: contrast media used during coronary angiography
Trial: NCT02449954
Drug: Intravenous ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group III: received IV 30 mg ketorolac tromethamine
Trial: NCT00628953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg twice a day
Trial: NCT02927873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
Trial: NCT02034474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously via iv drip over 60 min
Trial: NCT03105518
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5, 1 mcg/kg
Trial: NCT03105518
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single + Oxycodone
Trial: NCT02387619
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days
Trial: NCT02387619
Drug: Rosuvastatin and Telmisartan/Amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
Trial: NCT01927419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching nivolumab
Trial: NCT02231294
Drug: Sifrol®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01578057
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
Trial: NCT00530530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02947022
Drug: Calcium DTPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart.
Trial: NCT02947022
Drug: Zinc DTPA
RxNorm normalized name: zinc-DTPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart.
Trial: NCT04427917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo repeated doses
Trial: NCT00383721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDI twice a day for 26 weeks
Trial: NCT00946569
Drug: JNJ39758979
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
Trial: NCT00946569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo once daily orally for 12 weeks.
Trial: NCT03623282
Drug: Synatura® 15 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive Synatura® 15 mL every day three times for 3 months.
Trial: NCT00592553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to ataluren will be administered as the schedule specified in the respective arm.
Trial: NCT03304470
Drug: ATx201 2% Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anhydrous Cream
Trial: NCT03304470
Drug: ATx201 Cream Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anhydrous Cream
Trial: NCT01115738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose administered once orally
Trial: NCT03716518
Drug: Tonifying Spleen and Kidney Sequential Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.